References
- National Institute on Drug Abuse. Prescription drugs: abuse and addiction. Research Report Series. NIH Publication 05–4881. Rockville (MD); 2005
- Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. DHHS publication SMA 07–4293. Rockville (MD): Office of Applied Studies; 2007
- Huang B, Dawson DA, Stinson FS, et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006;67:1062–73
- McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health 2006;54:269–78
- Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2005: National estimates of drug-related emergency department visits. DHHS publication (SMA) 07–4256. Rockville (MD): Office of Applied Studies; 2006
- American Psychiatric Association. Substance-related disorders. In: Diagnostic and statistical manual of mental disorders, 4th ed. Arlington (VA): American Psychiatric Association; 2000. p. 191–9
- Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: national findings. DHHS publication SMA 06–4194. Rockville (MD): Office of Applied Studies; 2006
- Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national results on adolescent drug use: overview of key findings 2005. NIH publication 06–5882. Bethesda (MD): National Institute on Drug Abuse; 2006
- Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Overall, illicit drug use by American teens continues gradual decline in 2007. Ann Arbor (MI): University of Michigan News Service. Available at: www.monitoringthefuture.org [last accessed 18 December 2007]
- Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use, 1975–2005, vol II, college students and adults ages 19–45. NIH publication 06–5884. Bethesda (MD): National Institute on Drug Abuse; 2006
- Carise D, Dugosh KL, McLellan AT, et al. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 2007;164:1750–6
- National Center on Addiction and Substance Abuse at Columbia University. ‘You’ve got drugs!’ IV: prescription drug pushers on the Internet. A CASA white paper, 2007
- Forman RF, Marlowe DB, McLellan AT. The Internet as a source of drugs of abuse. Curr Psychiatry Rep 2006;8:377–82
- McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;99:96–106
- McCabe SE, Teter CJ, Boyd CJ. Illicit use of prescription pain medication among college students. Drug Alcohol Depend 2005;77:37–47
- Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26:1501–10
- Teter CJ, McCabe SE, Cranford JA, et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005;53:253–62
- Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408–14
- Upadhyaya HP, Rose K, Wang W, et al. Attention-deficit/ hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 2005;15:799–809
- Missed opportunity: national survey of primary care physicians and patients on substance abuse. New York (NY): Columbia University National Center on Addiction and Substance Abuse; 2000. Available at: www.casacolumbia.org/absolutenm/templates/Home.aspx [last accessed 11 July 2007]
- Knight JR, Sherritt L, Shrier LA, et al. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med 2002;156:607–14
- Ewing JA. Detecting alcoholism: the CAGE questionnaire. J Am Med Assoc 1984;252:1905–7
- Riggs PD. Treating adolescents for substance abuse and comorbid psychiatric disorders. NIDA Science and Practice Perspectives 2003;2:18–28
- Whitmore EA, Riggs PD. Developmentally informed diagnostic and treatment considerations in comorbid conditions. In: Liddle HA, Rowe CL, editors. Adolescent substance abuse: research and clinical advances. Cambridge: Cambridge University Press; 2006. p. 264–83
- Koob GF. Hedonic valence, dopamine and motivation. Mol Psychiatry 1996;1:186–9
- Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004;47(Suppl 1):3–13
- Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006;83S:S8–S14
- Mansbach RS, Moore RA Jr. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend 2006;83S:S15–S22
- McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 2006;83S:S52–S62
- Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83S:S4–S7
- Wright C IV, Kramer ED, Zalman MA, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006;83S:S68–S76
- Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991;86:1601–6
- Griffiths RR, McLeod DR, Bigelow GE, et al. Comparison of diazepam and oxazepam: preference, liking and extent of abuse. J Pharmacol Exp Ther 1984;229:501–8
- Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162:1432–40
- Fudala PJ, Bridge TP, Herbert S, et al.; for the Buprenorphine/ Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New Engl J Med 2003;349:949–58
- Brady KT. Medical treatment of opiate dependence: expanding treatment options. Am J Psychiatry 2007;164:702–4
- Findling RL. Prodrugs for ADHD hold promise. Clin Psychiatr News 2006;34:17 [editorial]
- Jasinski D, Krishnan S. Abuse liability of intravenous lisdexamfetamine dimesylate (LDX; NRP104). Poster presented at: US Psychiatric & Mental Health Congress, New Orleans, Louisiana; 17 November 2006
- Jasinski D, Krishnan S. A double-blind, randomized, placeboand active-controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers. Poster presented at: US Psychiatric & Mental Health Congress, New Orleans, Louisiana, 17 November 2006 [poster 236]